Pluri INC 8-K filings

Pluri Inc. reports ongoing constructive discussions with the European Investment Bank regarding its 50 million financing agreement, with a focus on resolving matters related to a 20 million disbursed tranche.

Pluri Inc. received a notice from Nasdaq indicating non-compliance with continued listing rules, with 180 days to regain compliance.

Pluri Inc. announced a private placement of common shares and warrants, raising approximately $2.5 million from Chutzpah Holdings LP, an entity beneficially owned by an existing director.

Pluri Inc. announced it has regained compliance with Nasdaq's minimum market value requirement, resolving a previous deficiency.

Pluri Inc. received a notice from Nasdaq for non-compliance with listing rules, including a minimum market value of listed securities requirement.

Pluri Inc. announced a $2.5 million private placement with Chutzpah Holdings LP, led by director Alexandre Weinstein, alongside key board appointments and RSU grants for executive and board compensation.

Pluri Inc.'s Board of Directors approved significant equity awards for CEO Yaky Yanay, recognizing fiscal year 2025 performance.

Pluri Inc. announced it has regained compliance with Nasdaq's Audit Committee independence requirements following the election of a new independent director.

Pluri Inc. announced the appointment of Eitan Ajchenbaum, a seasoned financial expert, to its Board of Directors, where he will also chair the Audit Committee.

Pluri Inc. announced that a director was not re-elected at its annual meeting, leading to non-compliance with Nasdaq's audit committee requirements, for which it has received a cure period.

PLURI Inc. announced the rescheduling of its 2025 Annual Meeting of Shareholders from May 23, 2025, to June 30, 2025, with the record date remaining May 23, 2025.

Pluri Inc. has regained compliance with Nasdaq Listing Rule 5550(b)(2) after demonstrating a market value of listed securities of $35 million or greater for 10 consecutive business days.

Pluri Inc. announces the date and location for its 2025 Annual Meeting of Shareholders, along with deadlines for shareholder proposals.

Pluri Inc. successfully completes the acquisition of a 71% equity stake in Kokomodo Ltd. for $4.5 million in common shares.

Pluri Inc. amended its Securities Purchase Agreement with an investor, exchanging common shares for pre-funded warrants to comply with Nasdaq rules.

Pluri Inc.'s subsidiary, Pluri Biotech Ltd., received a notice of termination from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) for a $4.2 million contract to develop PLX-R18 cell therapy.

Pluri Inc. announces the date for its 2025 Annual Meeting of Shareholders and sets deadlines for shareholder proposals.

Pluri Inc. enters into a share purchase agreement to acquire a controlling interest in Kokomodo, a cocoa cultivation company, for $4.5 million paid in Pluri common shares.

Pluri Inc. announces a private placement offering with Merchant Adventure Fund, L.P., for $3.5 million, involving common shares and warrants.

Pluri Inc. has entered into a securities purchase agreement for a $6.5 million private placement and a binding term sheet to acquire a majority stake in Kokomodo Ltd.

Pluri Inc. has been granted an extension until May 24, 2025, by Nasdaq to regain compliance with minimum stockholders' equity requirements after initially failing to meet the listing standards.

Pluri Inc. received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement for continued listing.

Pluri Inc. has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement, resolving a previous deficiency notice.

Pluri Inc. has been granted an extension until November 24, 2024, by Nasdaq to regain compliance with minimum stockholders' equity requirements after previously receiving a deficiency notice.

Pluri Inc. has announced a $1 million proof of concept agreement with a major international agriculture corporation to develop a solution for increasing global vegetable product supply using Pluri's 3D cell expansion technology.

Pluri Inc. has announced the resignation of its CFO, Chen Franco-Yehuda, effective September 30, 2024, and the appointment of Liat Zalts as her successor on the same date.

Pluri Inc. held its 2024 Annual Meeting of Stockholders on June 25, 2024, where directors were elected and the company's independent auditor was ratified.

Ever After Foods, a majority-owned subsidiary of Pluri Inc., has entered into a share purchase agreement to raise $10 million for its B2B cultivated meat technology platform.

Pluri Inc. received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement for continued listing.

Pluri Inc. has regained compliance with Nasdaq's minimum bid price requirement after its share price closed at or above $1.00 for ten consecutive business days.